Post hoc analysis of the phase 3 PRECISION trial in 147 participants with CKD and resistant hypertension: at week 4, office systolic BP fell by 13.5 and 16.6 mm Hg with aprocitentan 12.5 and 25 mg versus 4.4 mm Hg with placebo; early peripheral oedema was most common.
Secondary analysisn = 147
Rossignol et al. Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension